Application of trans-adamantanamine derivative or salt thereof
By modifying the structure of ambroxol and developing trans-adamantane ammonia derivatives and its salts, the problem of side effects and poor efficacy of drugs for treating lung injury and chronic cough in the existing technology has been solved, and more effective treatment of lung injury and cough has been achieved. , reducing side effects and significantly increasing sputum production and phenol red excretion.
Patent Information
- Application Number
- CN202110284357.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2021-03-17
- Publication Date
- 2022-07-01
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing technology lacks effective drugs for the treatment of lung injury and chronic cough, especially acute lung injury and refractory cough, and existing drugs such as ambroxol have side effects, such as constipation and drowsiness.
By structurally modifying ambroxol, trans-adamantane ammonia derivatives and their pharmaceutically acceptable salts were developed, prepared by condensation reaction and reduction reaction, and used to prevent or treat respiratory diseases, including lung injury and acute pulmonary disease. Injury, acute respiratory distress syndrome, cough and chronic cough.
Trans-amantadine derivatives and their hydrochloride significantly improve the therapeutic effect on lung injury and cough, are superior to existing drugs, reduce side effects, significantly increase sputum production and phenol red excretion, and have better of medicinal efficacy.